Novartis | NOVN - Passività Correnti





Passività Correnti Cambiamento Data
AbbVie USD 43.29B 3.9B 2025-12
Alcon AG USD 3.05B 59M 2025-12
Almirall EUR 350.64M 52.12M 2025-12
Amgen USD 25.49B 3.7B 2025-12
AstraZeneca USD 30.62B 3.44B 2025-12
Autolus Therapeutics Ltd USD 73.44M 9.63M 2025-12
Bayer EUR 32.58B 3.63B 2025-12
Biogen USD 3.35B 59.4M 2025-12
Bristol-Myers Squibb USD 28.14B 608M 2025-09
Eli Lilly USD 35.23B 4.91B 2025-12
Fresenius EUR 9.56B 1.27B 2025-09
Fresenius Medical Care EUR 6.25B 485.68M 2025-12
Galapagos EUR 152.86M 213.7M 2025-12
Genmab DKK 1.43B 686M 2025-12
Gilead Sciences USD 11.81B 485M 2025-12
GlaxoSmithKline GBP 21.39B 57M 2025-12
GRIFOLS EUR 2.02B 135.85M 2025-12
Hikma Pharmaceutical USD 1.45B 603M 2025-12
J&J USD 54.13B 3.26B 2025-12
Lonza CHF 3.57B 421M 2025-12
Merck EUR 9.04B 405M 2025-12
Merck USD 28.63B 2.59B 2025-09
Novartis USD 27.28B 4.72B 2025-12
Novartis USD 27.28B 4.72B 2025-12
Novo Nordisk DKK 215.66B 18.7B 2025-12
Orion EUR 560.3M 9.8M 2025-12
Pfizer USD 36.6B 1.13B 2025-09
Philips EUR 7.51B 479M 2025-12
Recordati EUR 1.04B 24.44M 2025-09
Regeneron Pharmaceuticals USD 4.37B 56.7M 2025-12
Roche Holding CHF 28B 421M 2025-12
Sanofi EUR 28.35B 3.76B 2025-12
UCB EUR 4.4B 470M 2025-12